Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. LDL-C between 100 and 190 mg/dL~2. Hepatic fat under 6.2% per MRS~Exclusion Criteria:~1. Pregnant or lactating females~2. Uncontrolled hypertension \>180/95 mmHg~3. Chronic renal insufficiency - serum creatinine \>2.5 mg/dL at screen~4. Liver disease; i.e., hepatitis, cirrhosis~5. Major surgery within 3 months of screen~6. Cardiac insufficiency~7. Hx of malignancy other than basal or squamous cell within past 5 yrs~8. Participation in any investigational drug study within 6 wks of screen~9. Prior exposure to AEGR-733 in past 12 months~10. Serious or unstable medical or psychological conditions~11. More than one alcoholic drink per day~12. Regular consumption of grapefruit juice or meds known to be metabolized by CYP 3A4~13. Currently taking corticosteroids~14. Other lipid-lowering meds (washout permitted)~15. Fish oil, niacin grater than 200 mg/day and herbal weight loss products (washout permitted)~16. Acute CVD or event within previous 6 months~17. Diabetes Mellitus~18. Hepatitis B or C~19. Medicated COPD~20. Idiopathic pulmonary fibrosis~21. G.I. disorders that cause chronic diarrhea~22. Fasting triglycerides =/\> 400 mg/dL~23. Body Mass Index \> 35kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): 2.5 mg AEGR-733
- 3 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733
- 4 (Type: ACTIVE_COMPARATOR): 7.5 mg AEGR-733
- 5 (Type: ACTIVE_COMPARATOR): 10 mg AEGR-733
- 6 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 20 mg atorvastatin
- 7 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 145 mg fenofibrate
- 8 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 10 mg ezetimibe

Based on this trial design, predict the completion outcome and termination type (if applicable).